BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE

Their core work

BfArM is Germany's Federal Institute for Drugs and Medical Devices — the national regulatory authority responsible for approving pharmaceuticals, medical devices, and overseeing pharmacovigilance. In H2020, they bring deep regulatory science expertise to health research consortia, particularly around drug identification standards (IDMP), electronic health record interoperability, and rare disease data frameworks. Their role bridges the gap between clinical research outcomes and the regulatory requirements needed to bring treatments and digital health tools to market across Europe.

What they specialise in

How they've shifted over time

BfArM's early H2020 involvement (2016-2018) centered on clinical data and disease-specific research — pharmacogenomics (U-PGx), hematological cancer big data (HARMONY), and organ-on-a-chip technology (EUROoC). From 2019 onward, their focus shifted decisively toward regulatory infrastructure: drug identification standards (UNICOM/IDMP), cross-border eHealth interoperability (X-eHealth), and building regulatory science capacity (STARS). This evolution reflects a move from contributing to clinical research projects toward shaping the regulatory and data standards that govern European health systems.

BfArM is positioning itself as a key player in European health data standardization and regulatory harmonization — expect future involvement in digital health regulation, AI in medicine governance, and cross-border pharmaceutical data systems.

How they like to work

BfArM operates primarily as a specialist participant in large consortia (299 unique partners across 37 countries), contributing regulatory authority expertise rather than leading projects. They coordinated only one project (STARS, focused on regulatory science training), which aligns with their role as a government body that advises and regulates rather than drives research agendas. Their broad partner network and willingness to join as third party or partner suggests they are accessible collaborators — valued for the regulatory legitimacy and domain knowledge they bring to any consortium.

With 299 unique consortium partners across 37 countries, BfArM has one of the broadest collaborative networks possible for an organization with just 8 projects — a direct result of joining very large pan-European consortia like HARMONY (multi-country hematology alliance) and EJP RD (rare diseases joint programme). Their reach is thoroughly pan-European with no obvious geographic bias.

What sets them apart

BfArM is not a university or research lab — it is Germany's national medicines and medical devices regulator. This gives consortium partners something no academic institution can: direct insight into how regulatory approval processes work and what standards will be required. For any project that needs to demonstrate a pathway from research to market authorization, or that deals with health data standards and cross-border compliance, BfArM's involvement adds immediate credibility and practical regulatory knowledge.

Highlights from their portfolio

• UNICOM
  Largest funded project (EUR 711K) — working on global medicine identification standards (IDMP), directly shaping how drugs are identified and tracked across borders.
• STARS
  Their only coordinated project — focused specifically on strengthening regulatory science training across European academia, reflecting their core institutional mission.
• HARMONY
  Major European big data alliance for blood cancers with a massive consortium, where BfArM contributed regulatory and data governance expertise to real-world patient data collection.